InMed Gets Conditional Approval for TSX Listing

Cannabis Investing News

InMed Pharmaceuticals announced it received conditional approval from the TSX to list its common shares in the exchange.

InMed Pharmaceuticals (CSE:IN; OTCQB:IMLFF) announced it received conditional approval from the Toronto Stock Exchange (TSX) to list its common shares in the exchange.

As quoted in the press release:

Final approval of the listing on the TSX remains subject to InMed fulfilling certain customary listing conditions of the TSX on or before the TSX-imposed deadline of May 29, 2018. The Company expects that it will satisfy such conditions in advance of the TSX-imposed deadline. Upon listing on the TSX, the Common Shares will continue to trade under the symbol ‘IN’.

“Graduating to the TSX is a significant accomplishment for InMed,” said Eric A. Adams, CEO & President. “This milestone furthers our corporate goal of securing a leadership position in this high-growth sector. InMed is one of only a few pure-play cannabinoid biopharmaceutical companies to be trading on one of the world’s senior stock exchanges.”

Click here to read the full press release.

approval biopharmaceutical companies cannabinoid inmed pharmaceuticals toronto Cannabis Investing